Imatinib Completed Phase 2 Trials for Stage IIIB Melanoma / Stage IIIc Melanoma / Acral Lentiginous Malignant Melanoma / Stage IV Melanoma / Stage IIIA Melanoma / Recurrent Melanoma Treatment

IndicationsStatusPurposePhase
CompletedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00470470Imatinib Mesylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery